Convalescent Plasma Therapy in Late-State, Severe COVID-19 Infection

被引:2
|
作者
Kumar, Neil R. [1 ]
Karanam, Veena C. [2 ]
Kumar, Shari [3 ]
Kumar, Sunil D. [4 ,5 ]
机构
[1] Univ Miami, Jackson Mem Hosp, Internal Med, Miami, FL 33136 USA
[2] Univ Miami, Miller Sch Med, Miami, FL USA
[3] Columbia Univ, Coll Dent Med, New York, NY USA
[4] Broward Hlth Med Ctr, Pulm Crit Care, Ft Lauderdale, FL 33316 USA
[5] Broward Hlth Med Ctr, 1600 S Andrews Ave, Ft Lauderdale, FL 33316 USA
关键词
convalescent plasma; COVID-19; severe; late stage; life threatening;
D O I
10.14423/SMJ.0000000000001546
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ObjectivesCurrent evidence favors plasma to be effective against coronavirus disease 2019 (COVID-19) in critically ill patients in the early stages of infection. We investigated the safety and efficacy of convalescent plasma in specifically late-stage (designated as after 2 weeks of hospital admission) severe COVID-19 infection. We also conducted a literature review on the late-stage use of plasma in COVID-19.MethodsThis case series examined eight COVID-19 patients admitted to the intensive care unit (ICU) who met criteria for severe or life-threatening complications. Each patient received one dose (200 mL) of plasma. Clinical information was gathered in intervals of 1 day pretransfusion and 1 hour, 3 days, and 7 days posttransfusion. The primary outcome was effectiveness of plasma transfusion, measured by clinical improvement, laboratory parameters, and all-cause mortality.ResultsEight ICU patients received plasma late in the course of COVID-19 infection, on average at 16.13 days postadmission. On the day before transfusion, the averaged initial Sequential Organ Failure Assessment (SOFA) score, PaO2:FiO(2) ratio, Glasgow Coma Scale (GCS), and lymphocyte count were 6.5, 228.03, 8.63, and 1.19, respectively. Three days after plasma treatment, the group averages for the SOFA score (4.86), PaO2:FiO(2) ratio (302.73), GCS (9.29), and lymphocyte count (1.75) improved. Although the mean GCS improved to 10.14 by posttransfusion day 7, the other means marginally worsened with an SOFA score of 5.43, a PaO2:FiO(2) ratio of 280.44, and a lymphocyte count of 1.71. Clinical improvement was noted in six patients who were discharged from the ICU.ConclusionsThis case series provides evidence that convalescent plasma may be safe and effective in late-stage, severe COVID-19 infection. Results showed clinical improvement posttransfusion as well as decreased all-cause mortality in comparison to pretransfusion predicted mortality. Randomized controlled trials are needed to conclusively determine benefits, dosage, and timing of treatment.
引用
收藏
页码:427 / 433
页数:7
相关论文
共 50 条
  • [31] Convalescent plasma (CP) therapy in patients with COVID-19
    Cakir, Banu
    [J]. TRANSFUSION AND APHERESIS SCIENCE, 2021, 60 (01)
  • [32] Convalescent plasma therapy in obese severe COVID-19 adolescents: Two cases report
    Cesilia, Citra
    Ridar, Elmi
    Suryawan, Nur
    Nataprawira, Heda Melinda
    [J]. ANNALS OF MEDICINE AND SURGERY, 2021, 72
  • [33] Immunomodulation Effect of Convalescent Plasma Therapy in Severe-Critical COVID-19 Patients
    Fitriah, Munawaroh
    Putri, Aditea Etnawati
    Semedi, Bambang Pujo
    Atika, Atika
    Tambunan, Betty Agustina
    [J]. OPEN ACCESS EMERGENCY MEDICINE, 2023, 15 : 109 - 118
  • [34] Severe COVID-19 in Patients with B Cell Alymphocytosis and Response to Convalescent Plasma Therapy
    Jonathan London
    David Boutboul
    Karine Lacombe
    France Pirenne
    Beate Heym
    Valérie Zeller
    Antoine Baudet
    Amani Ouedrani
    Alice Bérezné
    [J]. Journal of Clinical Immunology, 2021, 41 : 356 - 361
  • [35] Case Report: Convalescent Plasma, a Targeted Therapy for Patients with CVID and Severe COVID-19
    Van Damme, Karel F. A.
    Tavernier, Simon
    Van Roy, Nele
    De Leeuw, Elisabeth
    Declercq, Jozefien
    Bosteels, Cedric
    Maes, Bastiaan
    De Bruyne, Marieke
    Bogaert, Delfien
    Bosteels, Victor
    Hoste, Levi
    Naesens, Leslie
    Maes, Piet
    Grifoni, Alba
    Weiskopf, Daniela
    Sette, Alessandro
    Depuydt, Pieter
    Van Braeckel, Eva
    Haerynck, Filomeen
    Lambrecht, Bart N.
    [J]. FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [36] Severe COVID-19 in Patients with B Cell Alymphocytosis and Response to Convalescent Plasma Therapy
    London, Jonathan
    Boutboul, David
    Lacombe, Karine
    Pirenne, France
    Heym, Beate
    Zeller, Valerie
    Baudet, Antoine
    Ouedrani, Amani
    Berezne, Alice
    [J]. JOURNAL OF CLINICAL IMMUNOLOGY, 2021, 41 (02) : 356 - 361
  • [37] COVID-19 convalescent plasma
    Tobian, Aaron A. R.
    Cohn, Claudia S.
    Shaz, Beth H.
    [J]. BLOOD, 2022, 140 (03) : 196 - 207
  • [38] Convalescent Plasma for Covid-19
    Paneth, Nigel
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (10): : 955 - 955
  • [39] Convalescent Plasma and COVID-19
    Malani, Anurag N.
    Sherbeck, John P.
    Malani, Preeti N.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 324 (05): : 524 - 524
  • [40] Convalescent plasma for covid-19
    Estcourt, Lise J.
    Roberts, David J.
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2020, 370